Safety and tolerability of canakinumab, an IL-1β inhibitor, in type 2 diabetes mellitus patients: a pooled analysis of three randomised double-blind studies

BACKGROUND: We aimed to assess the safety and tolerability of different doses of canakinumab versus placebo in patients with type 2 diabetes mellitus (T2DM). METHODS: Data were pooled from three studies in 1026 T2DM patients with different routes of administration, treatment regimens and follow-up d...

Descripción completa

Detalles Bibliográficos
Autores principales: Howard, Campbell, Noe, Adele, Skerjanec, Andrej, Holzhauer, Björn, Wernsing, Margaret, Ligueros-Saylan, Monica, Thuren, Tom
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4033489/
https://www.ncbi.nlm.nih.gov/pubmed/24884602
http://dx.doi.org/10.1186/1475-2840-13-94

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4033489/
https://www.ncbi.nlm.nih.gov/pubmed/24884602
http://dx.doi.org/10.1186/1475-2840-13-94

Ejemplares similares